Many studies have looked at the effect of PARP inhibitors on other solid tumors, as well as ovarian and breast cancer, the first shown to possess the BRCA mutations, including pancreatic and prostate cancer 38, 39. This evidence concerns the gene PARP1 and breast carcinoma.